Article Text

PDF
OC-036 A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury
  1. C Paulding,
  2. J Singer,
  3. S Lewitzky,
  4. E Leroy,
  5. F Y Zhao,
  6. L Klickstein,
  7. T Wright,
  8. J Meyer
  1. Translational Sciences, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA

Abstract

Introduction Lumiracoxib is a selective COX-2 inhibitor that was developed for the symptomatic treatment of osteoarthritis and acute pain. Concerns over liver injury, primarily at chronic doses >100 mg once daily, led to the withdrawal of lumiracoxib in most major drug markets worldwide. A genome-wide association study was performed to identify genetic markers associated with lumiracoxib-related liver injury.

Methods Using DNA (n=10 057) collected during the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), a multistaged case-control pharmacogenetic study was conducted to identify genetic markers associated with the risk of developing elevations of liver aminotransferases (ALT/AST) during treatment with lumiracoxib. TARGET was a 52-week, gastrointestinal clinical safety outcomes study which demonstrated that lumiracoxib (400 mg once daily) reduced the risk of a definite or probable upper GI ulcer complication by 79% compared to NSAIDs (naproxen 500 mg twice daily and ibuprofen 800 mg three times daily) in non-aspirin treated osteoarthritis patients.

Results Several single nucleotide polymorphisms (SNPs) from the MHC class II region on chromosome 6 were found to be associated with liver aminotransferase elevations five times the upper limit of normal (>5×ULN) in patients treated with lumiracoxib (top SNP p=2.8E-10). These findings were replicated in an independent set of patients with elevated aminotransferases (>3×ULN) (top SNP p=4.4E-12). To further refine the association results, HLA genotyping and analysis were conducted and a very strong association was identified (top HLA allele p=6.8E-25).

Conclusion The study described here identified a highly significant association between HLA alleles and lumiracoxib-related liver injury. These results offer the potential to improve the safety profile of lumiracoxib by excluding patients at elevated risk for developing liver injury.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.